EA200101272A1 - Антагонисты альфа-v интегриновых рецепторов - Google Patents
Антагонисты альфа-v интегриновых рецепторовInfo
- Publication number
- EA200101272A1 EA200101272A1 EA200101272A EA200101272A EA200101272A1 EA 200101272 A1 EA200101272 A1 EA 200101272A1 EA 200101272 A EA200101272 A EA 200101272A EA 200101272 A EA200101272 A EA 200101272A EA 200101272 A1 EA200101272 A1 EA 200101272A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- alpha
- antagonists
- receptors
- integral
- integrin receptors
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 150000002842 nonanoic acids Chemical class 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Данное изобретение относится к новым производным нонановой кислоты, их синтезу и применению в качестве антагонистов альфа V интегриновых рецепторов. Точнее, соединения данного изобретения являются антагонистами интегриновых рецепторов альфа V бэта3 и альфа V бэта5 и полезны для ингибирования резорбции кости, лечения и профилактики остеопороза и ингибирования васкулярного рестеноза, диабетической ретинопатии, дегенерации желтого пятна, развития кровеносных сосудов, атеросклероза, воспаления, воспалительного артрита, вирусного заболевания, рака и метастатического роста опухоли.Отчет о международном поиске был опубликован 2000.09.22.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13710199P | 1999-06-02 | 1999-06-02 | |
| US17921600P | 2000-01-31 | 2000-01-31 | |
| PCT/US2000/014901 WO2000072801A2 (en) | 1999-06-02 | 2000-05-30 | Alpha v integrin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200101272A1 true EA200101272A1 (ru) | 2002-06-27 |
Family
ID=26834930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200101272A EA200101272A1 (ru) | 1999-06-02 | 2000-05-30 | Антагонисты альфа-v интегриновых рецепторов |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6410526B1 (ru) |
| EP (1) | EP1187592B1 (ru) |
| JP (3) | JP3808707B2 (ru) |
| KR (1) | KR20020021380A (ru) |
| CN (1) | CN1589145A (ru) |
| AT (1) | ATE368462T1 (ru) |
| AU (1) | AU749351B2 (ru) |
| BG (1) | BG106232A (ru) |
| BR (1) | BR0011108A (ru) |
| CA (1) | CA2373937A1 (ru) |
| CY (1) | CY1107746T1 (ru) |
| CZ (1) | CZ20014308A3 (ru) |
| DE (1) | DE60035779T2 (ru) |
| DK (1) | DK1187592T3 (ru) |
| DZ (1) | DZ3263A1 (ru) |
| EA (1) | EA200101272A1 (ru) |
| EE (1) | EE200100642A (ru) |
| ES (1) | ES2288861T3 (ru) |
| HR (1) | HRP20010895A2 (ru) |
| HU (1) | HUP0302468A2 (ru) |
| IL (1) | IL146378A0 (ru) |
| IS (1) | IS6157A (ru) |
| NO (1) | NO323906B1 (ru) |
| PL (1) | PL353364A1 (ru) |
| PT (1) | PT1187592E (ru) |
| SK (1) | SK17442001A3 (ru) |
| TR (1) | TR200103431T2 (ru) |
| WO (1) | WO2000072801A2 (ru) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| JP2003520271A (ja) | 2000-01-24 | 2003-07-02 | メルク エンド カムパニー インコーポレーテッド | αｖインテグリン受容体拮抗薬 |
| WO2001096334A2 (en) | 2000-06-15 | 2001-12-20 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| ES2280383T3 (es) * | 2000-07-26 | 2007-09-16 | MERCK & CO., INC. | Antagonistas de receptores de integrina alfa v. |
| WO2002022616A2 (en) * | 2000-09-14 | 2002-03-21 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| WO2002028395A1 (en) * | 2000-10-04 | 2002-04-11 | Merck & Co., Inc. | Phosphoric acid salt of an integrin receptor antagonist |
| CA2432504A1 (en) * | 2001-01-03 | 2002-07-11 | Merck & Co., Inc. | Methods and compositions for treating periodontal disease |
| CN1247258C (zh) | 2001-04-24 | 2006-03-29 | 默克专利有限公司 | 使用抗血管生成剂和TNFα的联合疗法 |
| JP2005525368A (ja) * | 2002-03-04 | 2005-08-25 | メディミューン，インコーポレーテッド | インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法 |
| CA2478239A1 (en) * | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| BR0316876A (pt) | 2002-12-20 | 2005-10-25 | Pharmacia Corp | Compostos de tiazol e composição farmacêutica compreendendo o mesmo |
| EP1603906A2 (en) * | 2003-03-07 | 2005-12-14 | Merck Sharp & Dohme Ltd. | Process for synthesising useful intermediates for the preparation of alpha v beta 3 receptor antagonists |
| US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| US20090130098A1 (en) | 2006-01-18 | 2009-05-21 | Merck Patent Gmbh | Specific therapy using integrin ligands for treating cancer |
| ES2399159T3 (es) | 2007-01-18 | 2013-03-26 | Merck Patent Gmbh | Terapia y medicamento específicos usando ligandos de integrinas para el tratamiento del cáncer |
| CL2008000467A1 (es) | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
| EP2217238B1 (en) | 2007-11-08 | 2014-03-12 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| SG176103A1 (en) | 2009-05-25 | 2011-12-29 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
| CN105246889B (zh) | 2013-02-07 | 2018-07-31 | 赛弗卢尔生命科学公司 | 氟化整联蛋白拮抗剂 |
| US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| JP6215335B2 (ja) | 2013-09-24 | 2017-10-18 | 富士フイルム株式会社 | 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体 |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US9790222B2 (en) | 2015-02-19 | 2017-10-17 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| WO2017189828A1 (en) * | 2016-04-27 | 2017-11-02 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| JP2019524702A (ja) * | 2016-07-05 | 2019-09-05 | ザ ロックフェラー ユニバーシティー | テトラヒドロナフチルリジンペンタンアミドインテグリンアンタゴニスト |
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| MA46746A (fr) * | 2016-11-08 | 2019-09-18 | Bristol Myers Squibb Co | Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v |
| BR112019009129A2 (pt) * | 2016-11-08 | 2019-07-16 | Bristol-Myers Squibb Company | compostos mono e espirocíclicos contendo ciclobutano e azetidina como inibidores de alfa v integrina |
| EP4159727A1 (en) | 2017-02-28 | 2023-04-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| PE20211640A1 (es) | 2018-08-29 | 2021-08-24 | Morphic Therapeutic Inc | INHIBICION DE LA INTEGRINA xvß6 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3843798A (en) | 1973-03-12 | 1974-10-22 | Stanley Drug Products Inc | Methods and compositions for inducing resistance to bacterial infections |
| US5025025A (en) | 1989-06-28 | 1991-06-18 | Ciba-Geigy Corporation | (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity |
| HUT68769A (en) | 1991-05-07 | 1995-07-28 | Merck & Co Inc | FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE |
| WO1993009795A1 (en) | 1991-11-22 | 1993-05-27 | Yeda Research And Development Co. Ltd. | Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them |
| US5786373A (en) | 1992-10-14 | 1998-07-28 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| CA2190870A1 (en) | 1994-05-27 | 1995-12-07 | George D. Hartman | Compounds for inhibiting osteoclast-mediated bone resorption |
| CA2242877A1 (en) | 1996-01-16 | 1997-07-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| ATE212990T1 (de) | 1996-03-20 | 2002-02-15 | Hoechst Ag | Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten |
| JP2000508319A (ja) | 1996-04-10 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | αｖβ３拮抗薬 |
| US5668159A (en) | 1996-05-08 | 1997-09-16 | The Dupont Merck Pharmaceutical Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists |
| JP2002511052A (ja) | 1996-08-29 | 2002-04-09 | メルク エンド カンパニー インコーポレーテッド | インテグリンアンタゴニスト |
| ES2194223T3 (es) * | 1996-10-30 | 2003-11-16 | Merck & Co Inc | Antagonistas de la integrina. |
| EP0946164A4 (en) | 1996-10-30 | 2000-08-23 | Merck & Co Inc | INTEGRIN ANTAGONISTS |
| WO1998031359A1 (en) | 1997-01-17 | 1998-07-23 | Merck & Co., Inc. | Integrin antagonists |
| US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| AU738452B2 (en) | 1997-12-17 | 2001-09-20 | Merck & Co., Inc. | Integrin receptor antagonists |
| CA2315370A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| BR9813769A (pt) * | 1997-12-17 | 2000-10-10 | Merck & Co Inc | Composto, composição farmacêutica, e, processos para fabricar a mesma, para evocar um efeito antagonizante do receptor da integrina em um mamìfero em necessidade deste, para tratar ou prevenir uma condição mediada pelo antagonismo de um receptor da integrina em um mamìfero em necessidade deste, para inibir a reabsorção óssea em um mamìfero em necessidade deste, e para tratar o desenvolvimento tumoral em um mamìfero em necessidade deste. |
| PT1040111E (pt) | 1997-12-17 | 2005-10-31 | Merck & Co Inc | Antagonistas do receptor da integrina |
-
2000
- 2000-05-30 CA CA002373937A patent/CA2373937A1/en not_active Abandoned
- 2000-05-30 DE DE60035779T patent/DE60035779T2/de not_active Expired - Fee Related
- 2000-05-30 CN CNA00811157XA patent/CN1589145A/zh active Pending
- 2000-05-30 BR BR0011108-2A patent/BR0011108A/pt not_active IP Right Cessation
- 2000-05-30 SK SK1744-2001A patent/SK17442001A3/sk unknown
- 2000-05-30 DK DK00942652T patent/DK1187592T3/da active
- 2000-05-30 AT AT00942652T patent/ATE368462T1/de not_active IP Right Cessation
- 2000-05-30 PT PT00942652T patent/PT1187592E/pt unknown
- 2000-05-30 EP EP00942652A patent/EP1187592B1/en not_active Expired - Lifetime
- 2000-05-30 TR TR2001/03431T patent/TR200103431T2/xx unknown
- 2000-05-30 IL IL14637800A patent/IL146378A0/xx unknown
- 2000-05-30 EE EEP200100642A patent/EE200100642A/xx unknown
- 2000-05-30 PL PL00353364A patent/PL353364A1/xx not_active Application Discontinuation
- 2000-05-30 CZ CZ20014308A patent/CZ20014308A3/cs unknown
- 2000-05-30 HU HU0302468A patent/HUP0302468A2/hu unknown
- 2000-05-30 WO PCT/US2000/014901 patent/WO2000072801A2/en active IP Right Grant
- 2000-05-30 AU AU57246/00A patent/AU749351B2/en not_active Ceased
- 2000-05-30 JP JP2000620913A patent/JP3808707B2/ja not_active Expired - Fee Related
- 2000-05-30 ES ES00942652T patent/ES2288861T3/es not_active Expired - Lifetime
- 2000-05-30 KR KR1020017015498A patent/KR20020021380A/ko not_active Application Discontinuation
- 2000-05-30 DZ DZ003263A patent/DZ3263A1/fr active
- 2000-05-30 EA EA200101272A patent/EA200101272A1/ru unknown
- 2000-05-31 US US09/583,522 patent/US6410526B1/en not_active Expired - Fee Related
-
2001
- 2001-11-13 IS IS6157A patent/IS6157A/is unknown
- 2001-11-30 NO NO20015858A patent/NO323906B1/no not_active IP Right Cessation
- 2001-11-30 HR HR20010895A patent/HRP20010895A2/xx not_active Application Discontinuation
- 2001-12-18 BG BG106232A patent/BG106232A/xx unknown
-
2006
- 2006-03-29 JP JP2006091926A patent/JP2006232844A/ja not_active Withdrawn
- 2006-03-29 JP JP2006091925A patent/JP2006206604A/ja not_active Withdrawn
-
2007
- 2007-09-27 CY CY20071101242T patent/CY1107746T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200101272A1 (ru) | Антагонисты альфа-v интегриновых рецепторов | |
| DE69829996D1 (de) | Integrin-rezeptor-antagonisten | |
| DK1040111T3 (da) | Integrinreceptorantagonister | |
| DE69720771T2 (de) | Integrin antagonist | |
| DE69830806D1 (de) | Integrinrezeptor antagonisten | |
| ES2185009T3 (es) | Antagonistas de alfa y beta 3'. | |
| ATE353219T1 (de) | Alpha v integrin-rezeptor-antagonisten | |
| WO2002090325A3 (en) | Benzazepinone alpha v integrin receptor antagonists | |
| ATE320258T1 (de) | Dibenzoxazepin-alpha-v-integrin- rezeptorantagonist | |
| YU38300A (sh) | Antagonisti integrinskog receptora | |
| YU38200A (sh) | Antagonisti integrinskog receptora |